We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03128164
Recruitment Status : Active, not recruiting
First Posted : April 25, 2017
Last Update Posted : September 13, 2022
Sponsor:
Information provided by (Responsible Party):
Hutchmed ( Hutchison Medipharma Limited )

Brief Summary:
This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).

Condition or disease Intervention/treatment Phase
Lymphomas Drug: HMPL-689 Phase 1

Detailed Description:

Both Stage I and Stage II include the following periods: screening period, treatment period, safety follow-up period, and extended progression free survival (PFS) follow-up period, as defined in Dose Escalation Stage (Stage I).

Dose escalation will be performed according to a modified toxicity probability interval scheme-2 (mTPI-2).To further characterize safety and efficacy of HMPL-689 at RP2D, expansion stage of the study enrolled 144 patients with B cell lymphoma, including CLL/ SLL, FL, MZL, DLBCL, MCL and PTCL. Patients were treated with RP2D as starting dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II). Dose escalation will be performed according to a modified toxicity probability interval scheme-2 (mTPI-2). Expansion stage of the study enrolled 143 patients with B cell lymphoma, including CLL/SLL, FL, MZL, DLBCL, MCL and PTCL, Patients were treated with RP2D as starting dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
Actual Study Start Date : August 8, 2017
Estimated Primary Completion Date : August 3, 2023
Estimated Study Completion Date : September 3, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Six arm including in dose expansion stage by following:
  • Arm A: patients with MZL (subtype including nodal, extra-nodal and splenic) who received ≥ 1 previous line of systematic treatment and at least one line included CD20-directed regimen
  • Arm B: patients with CLL/SLL who received ≥ 1 previous line of systematic treatment and at least one of which included purine-based regimen or CD20-directed regimen
  • Arm C: patients with FL (grade 1, 2, and 3a) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
  • Arm D: patients with MCL who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
  • Arm E: patients with DLBCL (including GCB and non-GCB, Richter' transformation) who received ≥ 2 previous line of systematic treatment and at least one line included CD20-directed regimen
  • Arm F: patients with PTCL who received ≥ 2 previous line of systematic treatment
Drug: HMPL-689
Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.




Primary Outcome Measures :
  1. Dose limited toxicities evaluated with NCI CTCAE v4.03 [ Time Frame: within 28 days after the first dose ]
    Incidence of dose limited toxicities and associated dose of HMPL-689

  2. Objective response rate (ORR) [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Overall response rate (ORR) is defined as the proportion of patients who have a CR or PR


Secondary Outcome Measures :
  1. Maximum plasma concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug

  2. Time to reach maximum concentration calculated with Blood samples [ Time Frame: within 29 days after the first dose ]
    Blood samples will be taken to measure the levels of study drug


Other Outcome Measures:
  1. Adverse events evaluated by NCI CTCAE v4.03 [ Time Frame: from the first dose to within 30 days after the last dose ]
    Incidence of adverse events and associated dose of HMPL-689

  2. Complete response rate (CR rate) [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Complete response rate (CR rate) is defined as the proportion of patients who have a CR Other lymphomas: Lugano Response Criteria for Hodgkin and Non-Hodgkin's Lymphoma [the Revised Response Criteria for Malignant Lymphoma (Cheson 2014)

  3. Time to response (TTR) [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Time to response (TTR) is defined as the date from the first dose of study drug to the date of first CR or PR

  4. Duration of response (DoR) [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Duration of response (DoR): defined as the time from when the first CR or PR was achieved until the earlier of the first documentation of definitive disease progression or death from any cause Other lymphomas: Lugano Response Criteria for Hodgkin and Non-Hodgkin's Lymphoma [the Revised Response Criteria for Malignant Lymphoma (Cheson 2014)

  5. Clinical benefit rate (CBR): [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Clinical benefit rate (CBR): defined as the proportion of patients who have a CR/CRi, PR/PR-L or SD

  6. Progression-free survival (PFS) [ Time Frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner ]
    Progression-free survival (PFS) is defined as the time from the first dose to the first occurrence of progression or death from any cause, whichever occurs first



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed Informed Consent Form (ICF)
  2. Ability to comply with the protocol
  3. Age > 18 years old
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. Histologically confirmed lymphoma
  6. Failed of standard of care or no standard of care existed according to local guideline
  7. At least 1 bi-dimensionally measurable nodal disease, defined as >1.5 cm (extra-nodal lesion>1.0 cm ) in its largest dimension by computerized tomography (CT) scan is required for patients with lymphoma other than CLL; lesions in anatomical locations (such as extremities or soft tissue lesions) that are not well visualized by CT may be measured by magnetic resonance image (MRI) instead
  8. Expected survival of more than 24 weeks
  9. Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use double barrier contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral or parenteral), Implanon®, injectable or other avoidance of pregnancy measures during the study and for 30 days after the last day of treatment. Post-menopausal females (>45 years old and without menses for >1 year) and surgically sterilized females are exempt from this criterion

Exclusion Criteria:

  1. Patients with CNS(Central nervous system) involvement
  2. Any of the following laboratory abnormalities:

    Absolute neutrophil count < 1.5×109/L Hemoglobin <90 g/L Platelets< 100 ×109/L

  3. Inadequate organ function, defined by the following:

    Total bilirubin >1.5 x the upper limit of normal (ULN) with the following exception:

    • Patients with known Gilbert's disease who have serum total and direct bilirubin level ≤ 2.5 x the ULN and normal aspartate transaminase (AST) and alanine transaminase (ALT) may be enrolled

    AST or ALT >2.5 x the ULN with the following exception:

    • In the dose expansion stage:Patients with documented disease infiltration of the liver may have AST and ALT levels ≤ 5 x the ULN

    Serum creatinine >1.5 x the ULN or estimated creatinine clearance (Ccr) (i.e., estimated Glomerular Filtration Rate, [eGFR[ according to the method of Cockcroft-Gault )< 60 mL/min

  4. International normalized ratio (INR) >1.5 x the ULN or activated partial thromboplastin time (aPTT) >1.5 x the ULN or Prothrombin Time (PT) >1.5 x the ULN
  5. Serum amylase or lipase >ULN at screening
  6. Patients with presence of second primary malignant tumors within the last 5 years, with the exception of the following non-invasive malignancies after curative treatment:

    Basal cell carcinoma of the skin Squamous cell carcinoma of the skin Carcinoma in situ of the cervix Carcinoma in situ of the breast Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for≥ 1 year prior to randomization

  7. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
  8. Prior treatment with any PI3K inhibitors and discontinued due to disease progression
  9. Any anti-cancer therapy, including chemotherapy, radiotherapy within 3 weeks prior to initiation of study treatment
  10. G-CSF/blood transfusion is prohibited 7 days before the screening hematology test
  11. Any steroid therapy or approved targeted small molecule agents for anti-neoplastic intent within 7 days or approximately 5 half-lives, whichever is the longer, prior to initiation of study treatment
  12. Any monoclonal antibody for anti-neoplastic intent within 6 weeks or 2 half-lives, whichever is the longer, prior to initiation of study treatment
  13. Prior use of any anti-cancer vaccine
  14. Prior administration of radioimmunotherapy within 3 months prior to initiation of study treatment
  15. Prior use of any drug that is a strong inducer of CYP3A4, strong inhibitor of CYP3A4 within 2 weeks prior to initiation of study treatment (refer to Appendix 13)
  16. Prior autologous transplant within 6 months prior to initiation of study treatment
  17. Prior allogeneic stem cell transplant within 6 months prior to initiation of study treatment or with any evidence of active graft versus host disease or requirement for immunosuppressants within 21 days prior to initiation of study treatment
  18. Clinically significant active infection (e.g., pneumonia)
  19. Major surgical procedure within 4 weeks prior to initiation of study treatment
  20. Treatment within a clinical study of an investigational agent or using an investigational device within 30 days prior to initiation of study treatment
  21. Adverse events from prior anti-cancer therapy that have not resolved to Grade 1, except for alopecia
  22. Pregnant (positive pregnancy test) or lactating women
  23. New York Heart Association (NYHA) Class II or greater congestive heart failure
  24. Congenital long QT syndrome or QTc > 450 msec
  25. Currently use medication known to cause QT prolongation or torsades de pointes
  26. History of myocardial infarction or unstable angina within 6 months prior to initiation of study treatment
  27. History of stroke or transient ischemic attack within 6 months prior to initiation of study treatment
  28. Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
  29. History of inflammatory bowel disease (e.g., Crohn disease or ulcerative colitis)
  30. History of drug-induced pneumonitis
  31. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03128164


Locations
Layout table for location information
China, Hubei
TongJi Medical College Huazhong University of Science& Technology
Wuhan, Hubei, China, 430030
China
Sun Yat-sen University cancer center
Guangzhou, China, 510060
Fudan University Shanghai Cancer Hospital
Shanghai, China, 200032
Sponsors and Collaborators
Hutchison Medipharma Limited
Investigators
Layout table for investigator information
Principal Investigator: Junning Cao, MD Fudan University
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT03128164    
Other Study ID Numbers: 2016-689-GLOB1
First Posted: April 25, 2017    Key Record Dates
Last Update Posted: September 13, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases